開発中の抗がん剤enzomenibがFDA「ブレイクスルーセラピー」に指定

Sumitomo Pharma Co. Ltd. published this content on October 27, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 23:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]